Results 91 to 100 of about 21,457 (213)
Rheumatology &Autoimmunity, EarlyView.Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama +4 more
wiley +1 more source
Swiss Medical Weekly, 2013 QUESTIONS UNDER STUDY: Clinical trials do not necessarily reflect the results obtained in daily clinical practice. By conducting a non-interventional, observational study with biologics in rheumatoid arthritis (RA) patients in Switzerland, we aimed ...
Jean Dudler +3 more
doaj +1 more source
Rheumatoid arthritis and spondyloarthropathy [PDF]
, 2013 Part 2 of the article can be found through this link: https://www.um.edu.mt/library/oar//handle/123456789/13280Rheumatoid arthritis (RA) and spondyloarthropathy are two groups of inflammatory joint disease.
Vassallo, Pierre
core
Infectious agents and inflammation. The role of microbiota in autoimmune arthritis [PDF]
, 2018 In higher vertebrates, mucosal sites at the border between the internal and external environments, directly interact with bacteria, viruses, and fungi.
D'Amelio, Raffaele +2 more
core +2 more sources
Evolving treatments for Sjögren disease: current approaches and emerging targets
Internal Medicine Journal, EarlyView.Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani +3 more
wiley +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundWe examined the cardiovascular risk of abatacept compared with tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis with and without diabetes mellitus (DM). Methods and ResultsWe conducted a cohort study of patients with
Eun Ha Kang +6 more
doaj +1 more source
Internal Medicine Journal, EarlyView.Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie +14 more
wiley +1 more source
Two decades of biologic and JAK inhibitor prescription patterns in the western region of Melbourne
Internal Medicine Journal, EarlyView.Abstract Background and Aim Safety concerns and medication shortages may influence prescribing practices in rheumatology. This study aimed to explore the impact of Janus kinase inhibitor (JAKi) safety warnings and the COVID‐19 pandemic on biologic and targeted‐synthetic disease‐modifying antirheumatic drug (b/tsDMARD) prescription patterns from 2002 to
Alexander Kwan +8 more
wiley +1 more source
RMD Open, 2019 Objectives To complete reporting of outcomes after total withdrawal of all rheumatoid arthritis (RA) therapy and re-treatment after flare in Assessing Very Early Rheumatoid arthritis Treatment study (NCT01142726).Methods Patients with early RA were ...
Daniel E Furst +6 more
doaj +1 more source
Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept [PDF]
, 2014 A patient affected by rheumatoid arthritis developed a squamous-cell carcinoma probably due to abatacept, according to Naranjo algorithm. The case describes this adverse reaction for the first time and highlights the need for additional studies to ...
Deidda, Arianna +7 more
core +1 more source